Genetic polymorphisms and prostate cancer risk.
The identification of common genetic polymorphisms that influence susceptibility to PC would allow an early risk assessment with earlier and therefore potentially more effective intervention by chemopreventive means. In this review we focus on published case-control studies and meta-analyses of the following polymorphic genes that may play a role in etiology of the androgen receptor (AR), the prostate-specific antigen (PSA), 5alpha-reductase type II gene (SRD5A2), cytochrome P450c17alpha (CYP17), cytochrome P4503A4 (CYP3A4) and a putative hereditary PC susceptibility gene, ELAC2.
Gsur
Andrea
A
Division of Applied and Experimental Oncology, Institute of Cancer Research, University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria. andrea.gsur@univie.ac.at
Feik
Elisabeth
E
Madersbacher
Stephan
S
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D017430:Prostate-Specific Antigen / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics*; D011944:Receptors, Androgen / Q000235:genetics; D018570:Risk Assessment; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics
C421605:ELAC2 protein, human; D009363:Neoplasm Proteins; D011944:Receptors, Androgen; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D013254:Steroid 17-alpha-Hydroxylase; C510163:CYP3A4 protein, human; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D017430:Prostate-Specific Antigen